Relay Therapeutics (RLAY) Experiences Sharp Decline After April Rally

Relay Therapeutics (RLAY) fell 12.84% to $13.03 on April 29, 2026, as investors took profits following a 74% surge in April. The decline followed positive data from its cancer treatment candidate, Zovegalisib, and the initiation of a Phase 3 clinical trial in combination with Pfizer’s atirmociclib.

By Angelica Ballesteros Wed, April 29, 2026 at 4:34 AM GMT+3 2 min read · Yahoo Finance · April 29, 2026, 01:34 UTC

Relay Therapeutics (RLAY) Experiences Sharp Decline After April Rally

Tickers: $PFE

Topics: analyst ratings clinical trial progress profit-taking stock price movement

Read the full article at Yahoo Finance

More World news

Spout Finance Integrates Ondo Stocks to Enable Interest-Free USDC Borrowing via Covered Calls PR Newswire · November 12, 2026, 14:30 UTC
Deswell Industries Announces Semi-Annual Dividend of $0.10 Per Share Seeking Alpha · November 12, 2026, 14:24 UTC
Nvidia Shares Plunge Following Announcement of CEO Jensen Huang's Resignation Seeking Alpha · November 12, 2026, 14:24 UTC
Archer Aviation Enters Multi-Year Partnership with Formula One Seeking Alpha · November 12, 2026, 14:16 UTC
Edgewell Personal Care Announces Quarterly Dividend of $0.15 Per Share Seeking Alpha · November 12, 2026, 14:16 UTC
Hudbay Minerals Announces Quarterly Dividend of CAD 0.01 Per Share Seeking Alpha · November 12, 2026, 14:16 UTC
Warby Parker Unveils AI-Powered Intelligent Eyewear Collection in Partnership with Google and Samsung Seeking Alpha · November 12, 2026, 14:17 UTC
Where Food Comes From Reports Q3 Revenue Growth and Improved Gross Margins Seeking Alpha · November 12, 2026, 14:17 UTC
Medical Care Technologies Inc. Reports Q3 Revenue Growth and Significant Net Income Increase Seeking Alpha · November 12, 2026, 14:17 UTC
Digi International Reports Record Fiscal 2026 Results and Announces Acquisition of Disruptive Technologies Motley Fool · November 12, 2026, 14:15 UTC